Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02329-18. doi: 10.1128/AAC.02329-18. Print 2019 Apr.

2.

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.

Gall J, Choi T, Riddle V, Van Wart S, Gibbons JA, Seroogy J.

Clin Pharmacol Drug Dev. 2019 Jan 16. doi: 10.1002/cpdd.653. [Epub ahead of print]

PMID:
30650259
3.

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function.

Komirenko AS, Riddle V, Gibbons JA, Van Wart S, Seroogy JD.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01128-18. doi: 10.1128/AAC.01128-18. Print 2018 Dec.

4.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):351. doi: 10.1007/s10928-018-9572-2.

PMID:
29446052
5.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

Miglis C, Rhodes NJ, Kuti JL, Nicolau DP, Van Wart SA, Scheetz MH.

Int J Antimicrob Agents. 2017 Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.

PMID:
28668683
6.

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Feb 14;:.

PMID:
28353185
7.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.

Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.

8.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1401-10. doi: 10.1128/AAC.01956-15.

9.

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J.

Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.

10.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

11.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

12.

Population-based meta-analysis of furosemide pharmacokinetics.

Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.

Biopharm Drug Dispos. 2014 Mar;35(2):119-33. doi: 10.1002/bdd.1874. Epub 2013 Nov 16.

PMID:
24151207
13.

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.

Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.

Biopharm Drug Dispos. 2013 Dec;34(9):527-39. doi: 10.1002/bdd.1863. Epub 2013 Oct 10.

PMID:
24123104
14.

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6348-50. doi: 10.1128/AAC.01748-13. Epub 2013 Sep 16.

15.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.

Raddad E, Melhem MR, Sloan-Lancaster JS, Miller JW, Van Wart SA, Rubino CM.

CPT Pharmacometrics Syst Pharmacol. 2013 Aug 21;2:e66. doi: 10.1038/psp.2013.43.

16.

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.

17.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.

Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.

J Clin Pharmacol. 2013 Nov;53(11):1155-67. doi: 10.1002/jcph.153. Epub 2013 Aug 14.

PMID:
23907740
18.

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.

Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.

Biopharm Drug Dispos. 2013 Sep;34(6):336-47. doi: 10.1002/bdd.1849. Epub 2013 Aug 6.

PMID:
23794414
19.

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3478-87. doi: 10.1128/AAC.02440-12. Epub 2013 May 13.

20.

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.

21.

Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy.

Yousef AM, Melhem M, Xue B, Arafat T, Reynolds DK, Van Wart SA.

Biopharm Drug Dispos. 2013 May;34(4):215-26. doi: 10.1002/bdd.1839. Epub 2013 Apr 29.

PMID:
23463618
22.

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Török ME, Van Wart SA, Mai PP, Reynolds DK, Caws M, Dung NT, Hien TT, Kulawy R, Farrar J, Ambrose PG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3244-53. doi: 10.1128/AAC.00064-11. Epub 2011 Apr 18.

23.

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2011 May;55(5):2113-21. doi: 10.1128/AAC.01430-10. Epub 2011 Feb 7.

24.

Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.

Marathe A, Van Wart S, Mager DE.

J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):223-35. doi: 10.1007/s10928-010-9190-0. Epub 2010 Dec 17.

25.

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.

Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A.

Antimicrob Agents Chemother. 2009 Oct;53(10):4422-8. doi: 10.1128/AAC.00231-09. Epub 2009 Jul 27.

26.

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM.

Diagn Microbiol Infect Dis. 2009 Apr;63(4):409-14. doi: 10.1016/j.diagmicrobio.2009.01.027. Epub 2009 Feb 26.

PMID:
19249182
27.

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Feb;63(2):155-9. doi: 10.1016/j.diagmicrobio.2008.10.011.

PMID:
19150707
28.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014.

PMID:
19073300
29.

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. Epub 2007 Oct 22.

30.

Population pharmacokinetics of tigecycline in healthy volunteers.

Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS.

J Clin Pharmacol. 2007 Jun;47(6):727-37.

PMID:
17519399
31.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

32.

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB.

Antimicrob Agents Chemother. 2006 Nov;50(11):3701-7. Epub 2006 Aug 28.

33.

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.

Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.

Antimicrob Agents Chemother. 2004 Dec;48(12):4766-77.

34.

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M, Jones RN.

Clin Infect Dis. 2004 Jun 1;38(11):1513-20. Epub 2004 May 12. Erratum in: Clin Infect Dis. 2005 Jan 15;40(2):341.

PMID:
15156435
35.

Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.

Meno-Tetang GM, Hon YY, Van Wart S, Jusko WJ.

Drug Metabol Drug Interact. 1999;15(1):51-70.

36.

Pharmacokinetics and leukocyte responses of recombinant human interleukin-10.

Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ.

Pharm Res. 1998 Dec;15(12):1895-901.

PMID:
9892475

Supplemental Content

Loading ...
Support Center